The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Natalya Davies - Intron Health - Analyst
: Thanks for taking my questions and congratulations on the encouraging data. Just a couple for me. Firstly, can we expect any additional suburb
analysis from the VIVA-MIND study or any additional data on transforming levels or weight loss topic blood pressure, any of those would be great.
And yes, any further analysis that we can expect on both of the trials. And then the second question is just on the kidney opportunities outside of
diabetic kidney disease such as fabric disease. Has the preclinical analysis started? Or is this subject to additional funding? Thank you.
Question: Natalya Davies - Intron Health - Analyst
: Sorry. And just on the opportunities outside of diabetic kidney disease, are there any updates on that front?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
DECEMBER 10, 2024 / 2:00PM, VVY.AS - Q3 2024 Vivoryon Therapeutics NV Earnings Call
Question: Natalya Davies - Intron Health - Analyst
: Great. Thank you so much.
Question: Lucy Codrington - Jefferies - Analyst
: Hi. Thank you for taking my questions. So just following on from that, you mentioned that there was a small proportion of patients with diabetic
kidney disease in this study. Can you tell us how many, if any, patients did have diabetic kidney disease across the two arms.
And then just related to that, any of the patients, are they on concomitant SGLT2 or GLP-1s, both within VIVA-MIND and in the VIVIAD study. And
then just on the final comment or a comment towards the end about extending the composition of master IP. Just what's driving confidence that,
that will be feasible for target exam? Thank you.
Question: Lucy Codrington - Jefferies - Analyst
: Yeah, I think so. Thank you.
Question: Joseph Hedden - Rx Securities Limited - Analyst
: Good afternoon. Thanks for taking my questions and congrats on this positive consistent data. Just on the plan for the Phase 2 DKD study the fact
that you've seen that these data are quite consistent with VIVA-MIND, VIVIAD, does that change the plan in any way, the recruitment size or any
factors of that study and then secondly, on the cash runway and the streamlining that you've been doing to extend it.
Has that affected any of the preclinical work that you were doing? Is there an intel that's now not being explored that was previously part of the
program? Thanks.
Question: Joseph Hedden - Rx Securities Limited - Analyst
: Okay, great. Thanks very much, Frank.
Question: Luisa Morgado - Van Lanschot Kempen N.V. - Analyst
: Hi Tim. Thank you for taking my questions. First of all, of course, congrats on the data, confirming your earlier findings. My first question in terms
of the VIVA-MIND study analysis. What are the main motives behind withdrawal by the subject themselves? Yeah, if you could elaborate on that.
Question: Luisa Morgado - Van Lanschot Kempen N.V. - Analyst
: Okay, clear. That's quite helpful. And in terms, maybe a question more for in terms of the expenses over the next quarters, what can we expect here
and when will the -- is the VIVA-MIND trial completely terminated altogether or when will that happen? Thank you.
Question: Luisa Morgado - Van Lanschot Kempen N.V. - Analyst
: Okay. All clear. Thank you for taking my questions.
| 
